Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer
By Simon A. Jones, B. Jenkins. Nature reviews. Immunology, 2018
942 citations recorded by the source corpus.
Subfields: Hematology, Immunology, Oncology
View Paper: https://www.semanticscholar.org/paper/436e538b3f6c3c50e746593754234485bac48392
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hematology
In Immunology
In Oncology
Citations in the corpus
- IL-6 in inflammation, autoimmunity and cancer (2020, background): “Other inhibitors against the IL-6–STAT3 signaling pathway are under development (19, 21, 24–26, 76, 374).”
- Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality (2020, neutral): “IL-6 can be produced by almost all stromal cells and immune system cells, such as B lymphocytes, T lymphocytes, macrophages, monocytes, dendritic cells, mast cells and other non-lymphocytes, such as fibroblasts, endothelial cells, keratinocytes, glomerular Mesangial cells and tumor cells [16] .”
- Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19) (2020, positive): “Dysregulated and continual synthesis of IL-6 has been shown to play a pathological role in chronic inflammation and infection (25, 26).”